Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice

Neuropharmacology

Volumn 63, Issue 3, 2012, Pages 450-459

  Quik, Maryka ^a   Park, Keon Min ^a   Hrachova, Maya ^a   Mallela, Archana ^a   Huang, Luping Z ^a   McIntosh, J Michael ^b,c   Grady, Sharon R ^d  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

6 Hydroxydopamine; Alpha6; Dyskinesia; l dopa; Nicotine; Parkinson's disease

Indexed keywords

BENSERAZIDE; BUPRENORPHINE; COTININE; DOPAMINE TRANSPORTER; LEVODOPA; NICOTINIC RECEPTOR; OXIDOPAMINE; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DYSKINESIA; FOREBRAIN; INVOLUNTARY MOVEMENT; LEVODOPA INDUCED DYSKINESIA; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; WILD TYPE;

EID: 84862018780     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.04.029     Document Type: Article

References (44)

1. 125I autoradiography J. Neurosci. Methods 32 1990 185 192
2. T. Bordia, S.R. Grady, J.M. McIntosh, and M. Quik Nigrostriatal damage preferentially decreases a subpopulation of {alpha}6{beta}2* nAChRs in mouse, monkey and Parkinson's disease striatum Mol. Pharmacol. 72 2007 52 61
3. T. Bordia, C. Campos, L. Huang, and M. Quik Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease J. Pharmacol. Exp. Ther. 327 2008 239 247
4. T. Bordia, C. Campos, J.M. McIntosh, and M. Quik Nicotinic receptor-mediated reduction in l-dopa-induced dyskinesias may occur via desensitization J. Pharmacol. Exp. Ther. 333 2010 929 938
5. S.P. Brooks, and S.B. Dunnett Tests to assess motor phenotype in mice: a user's guide Nat. Rev. Neurosci. 10 2009 519 529
6. J. Brotchie, and P. Jenner New approaches to therapy Int. Rev. Neurobiol. 98 2011 123 150
7. J.J. Buccafusco, and A.V. Terry Jr. The potential role of cotinine in the cognitive and neuroprotective actions of nicotine Life Sci. 72 2003 2931 2942
8. J.J. Buccafusco, J.W. Beach, and A.V. Terry Desensitization of nicotinic acetylcholine receptors as a strategy for drug development J. Pharmacol. Exp. Ther. 328 2009 364 370
9. P. Calabresi, M.D. Filippo, V. Ghiglieri, N. Tambasco, and B. Picconi Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap Lancet Neurol. 9 2010 1106 1117
10. A.M. Capelli, L. Castelletti, Y.H. Chen, H. Van der Keyl, L. Pucci, B. Oliosi, C. Salvagno, B. Bertani, C. Gotti, A. Powell, and M. Mugnaini Stable expression and functional characterization of a human nicotinic acetylcholine receptor with alpha6beta2 properties: discovery of selective antagonists Br. J. Pharmacol. 163 2011 313 329
11. M. Carta, and E. Bezard Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia Neuroscience 198 2011 245 251
12. M.A. Cenci, and M. Lundblad Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice Curr. Protoc. Neurosci. 2007 (Chapter 9), Unit 9 25
13. N. Champtiaux, Z.Y. Han, A. Bessis, F.M. Rossi, M. Zoli, L. Marubio, J.M. McIntosh, and J.P. Changeux Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice J. Neurosci. 22 2002 1208 1217
14. A.M. Dopico, and D.M. Lovinger Acute alcohol action and desensitization of ligand-gated ion channels Pharmacol. Rev. 61 2009 98 114
15. S. Duty Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease Br. J. Pharmacol. 161 2010 271 287
16. 3H]dopamine release from rat striatal slices in a calcium-dependent manner J. Pharmacol. Exp. Ther. 288 1999 905 911
17. G. Fisone, and E. Bezard Molecular mechanisms of l-DOPA-induced dyskinesia Int. Rev. Neurobiol. 98 2011 95 122
18. C.R. Gerfen, and D.J. Surmeier Modulation of striatal projection systems by dopamine Annu. Rev. Neurosci. 34 2011 441 466
19. C. Gotti, S. Guiducci, V. Tedesco, S. Corbioli, L. Zanetti, M. Moretti, A. Zanardi, R. Rimondini, M. Mugnaini, F. Clementi, C. Chiamulera, and M. Zoli Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement J. Neurosci. 30 2010 5311 5325
20. S.R. Grady, C.R. Wageman, N.E. Patzlaff, and M.J. Marks Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include alpha5 or alpha6 subunits and that mediate synaptosomal neurotransmitter release Neuropharmacology 62 2012 1935 1943
21. C. Guigoni, Q. Li, I. Aubert, S. Dovero, B.H. Bioulac, B. Bloch, A.R. Crossman, C.E. Gross, and E. Bezard Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia J. Neurosci. 25 2005 2102 2107
22. G. Halliday, A. Lees, and M. Stern Milestones in Parkinson's disease - clinical and pathologic features Mov. Disord. 26 2011 1015 1021
23. L. Huang, S.R. Grady, and M. Quik Nicotine reduces l-Dopa-Induced dyskinesias by acting at {beta}2 nicotinic receptors J. Pharmacol. Exp. Ther. 338 2011 932 941
24. L.Z. Huang, C. Campos, J. Ly, F.I. Carroll, and M. Quik Nicotinic receptor agonists decrease l-dopa-induced dyskinesias most effectively in moderately lesioned parkinsonian rats Neuropharmacology 60 2011 861 868
25. A. Kuryatov, and J. Lindstrom Expression of functional human alpha6beta2beta3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers Mol. Pharmacol. 79 2011 126 140
26. A. Lai, N. Parameswaran, M. Khwaja, P. Whiteaker, J.M. Lindstrom, H. Fan, J.M. McIntosh, S.R. Grady, and M. Quik Long-term nicotine treatment decreases striatal alpha6* nicotinic acetylcholine receptor sites and function in mice Mol. Pharmacol. 67 2005 1639 1647
27. S.G. Matta, D.J. Balfour, N.L. Benowitz, R.T. Boyd, J.J. Buccafusco, A.R. Caggiula, C.R. Craig, A.C. Collins, M.I. Damaj, E.C. Donny, P.S. Gardiner, S.R. Grady, U. Heberlein, S.S. Leonard, E.D. Levin, R.J. Lukas, A. Markou, M.J. Marks, S.E. McCallum, N. Parameswaran, K.A. Perkins, M.R. Picciotto, M. Quik, J.E. Rose, A. Rothenfluh, W.R. Schafer, I.P. Stolerman, R.F. Tyndale, J.M. Wehner, and J.M. Zirger Guidelines on nicotine dose selection for in vivo research Psychopharmacology (Berl.) 190 2007 269 319
28. Y.S. Mineur, and M.R. Picciotto Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis Trends Pharmacol. Sci. 31 2010 580 586
29. J.A. Obeso, M.C. Rodriguez-Oroz, B. Benitez-Temino, F.J. Blesa, J. Guridi, C. Marin, and M. Rodriguez Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease Mov. Disord. 23 Suppl. 3 2008 S548 S559
30. K.T. O'Leary, N. Parameswaran, J.M. McIntosh, and M. Quik Cotinine selectively activates a subpopulation of {alpha}3/{alpha}6{beta}2* nicotinic receptors in monkey striatum J. Pharmacol. Exp. Ther. 325 2008 646 654
31. D.C. Perry, D. Mao, A.B. Gold, J.M. McIntosh, J.C. Pezzullo, and K.J. Kellar Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain J. Pharmacol. Exp. Ther. 322 2007 306 315
32. M.R. Picciotto, N.A. Addy, Y.S. Mineur, and D.H. Brunzell It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood Prog. Neurobiol. 84 2008 329 342
33. K. Pietila, and L. Ahtee Chronic nicotine administration in the drinking water affects the striatal dopamine in mice Pharmacol. Biochem. Behav. 66 2000 95 103
34. M. Quik, and S. Wonnacott {alpha}6{beta}2* and {alpha}4{beta} 2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease Pharmacol. Rev. 63 2011 938 966
35. M. Quik, J.D. Sum, P. Whiteaker, S.E. McCallum, M.J. Marks, J. Musachio, J.M. McIntosh, A.C. Collins, and S.R. Grady Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice Mol. Pharmacol. 63 2003 1169 1179
36. M. Quik, H. Cox, N. Parameswaran, K. O'Leary, J.W. Langston, and D. Di Monte Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys Ann. Neurol. 62 2007 588 596
37. M. Quik, X.A. Perez, and S.R. Grady Role of alpha6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders Biochem. Pharmacol. 82 2011 873 882
38. O. Rascol, A. Lozano, M. Stern, and W. Poewe Milestones in Parkinson's disease therapeutics Mov. Disord. 26 2011 1072 1082
39. O. Salminen, K.L. Murphy, J.M. McIntosh, J. Drago, M.J. Marks, A.C. Collins, and S.R. Grady Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice Mol. Pharmacol. 65 2004 1526 1535
40. T. Schallert, S.M. Fleming, J.L. Leasure, J.L. Tillerson, and S.T. Bland CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury Neuropharmacology 39 2000 777 787
41. A.H. Schapira, and P. Jenner Etiology and pathogenesis of Parkinson's disease Mov. Disord. 26 2011 1049 1055
42. J.A. Sparks, and J.R. Pauly Effects of continuous oral nicotine administration on brain nicotinic receptors and responsiveness to nicotine in C57Bl/6 mice Psychopharmacology (Berl.) 141 1999 145 153
43. S. Threlfell, and S.J. Cragg Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons Front. Syst. Neurosci. 5 2011 11
44. T. Wichmann, M.R. DeLong, J. Guridi, and J.A. Obeso Milestones in research on the pathophysiology of Parkinson's disease Mov. Disord. 26 2011 1032 1041